

(19)



(11)

EP 3 247 271 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:

05.12.2018 Bulletin 2018/49

(21) Application number: **15700491.2**

(22) Date of filing: **19.01.2015**

(51) Int Cl.:

A61B 5/00 ^(2006.01) **A61B 5/0476** ^(2006.01)
A61B 5/0478 ^(2006.01) **A61B 5/157** ^(2006.01)
A61B 5/15 ^(2006.01) **A61B 5/155** ^(2006.01)
A61B 5/145 ^(2006.01) **A61M 5/142** ^(2006.01)
A61M 5/172 ^(2006.01)

(86) International application number:

PCT/EP2015/050855

(87) International publication number:

WO 2016/116127 (28.07.2016 Gazette 2016/30)

(54) **SYSTEM FOR ADJUSTING THE BLOOD GLUCOSE LEVEL OF A PERSON AND METHOD FOR ADJUSTING AN INSULIN DELIVERY DEVICE**

SYSTEM ZUR EINSTELLUNG DES BLUTZUCKERSPIEGELS EINER PERSON UND VERFAHREN
ZUR EINSTELLUNG EINER INSULINABGABEVORRICHTUNG

SYSTÈME D'AJUSTEMENT DU TAUX DE GLYCÉMIE D'UNE PERSONNE ET PROCÉDÉ
D'AJUSTEMENT D'UN DISPOSITIF D'ADMINISTRATION D'INSULINE

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(43) Date of publication of application:

29.11.2017 Bulletin 2017/48

(73) Proprietor: **T&W Engineering A/S**

3540 Lyngby (DK)

(72) Inventors:

• **TØPHOLM, Richard**
DK-3540 Lyngby (DK)

• **JENSEN, Rasmus Stig**

DK-2800 Lyngby (DK)

• **CHRISTENSEN, Erik Skov**

DK-3540 Lyngby (DK)

• **MADSEN, Rasmus Elsborg**

DK-2800 Lyngby (DK)

(56) References cited:

WO-A1-2012/069549 US-A1- 2011 118 578

US-A1- 2014 221 966 US-A1- 2014 278 123

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] The present invention relates to a system for adjusting the blood glucose level of a person. The invention more particularly relates to a system comprising an insulin delivery device configured to release insulin into the body of a person, as well as an EEG monitor having an EEG sensing part comprising EEG electrodes. The EEG monitor is adapted for being arranged in the ear region of the person with the EEG sensing part arranged subcutaneously at the scalp or arranged in the ear canal. The EEG monitor comprises an EEG signal processor arranged at the ear and adapted for identifying onset of hypoglycemia. The system further comprises a wireless communication link between the EEG monitor and the insulin delivery device.

Insulin delivery devices for continuous insulin infusion, such as insulin pumps, can be arranged to deliver insulin at a rate varying over the day and according to the needs of the person, or, the pump can deliver in response to a specific request made by the person.

There is a wish to combine insulin pumps with a blood glucose monitor, or a continuous glucose monitor (CGM), in order to obtain a continuous automatic control of the blood glucose for a person having diabetes.

A clinical important problem is the lack of possibility to directly control if the person is getting close to a condition of hypoglycemia. It is possible to detect an upcoming onset of hypoglycemia by analysis of the persons EEG.

[0002] US 8,348,842 B1 discloses a system comprising an insulin pump and sensors configured to produce an output related to the glycemic state. One type of sensor may be for measuring EEG.

US 6,572,542 B1 discloses a system where a combined processing of electrocardiogram signal and EEG signal is applied for detecting a hypoglycemic event. An event may result in delivery of insulin or glucagon to the patient.

[0003] The problem of these known systems is that there is no direct link between the EEG monitoring and the insulin delivery device, and therefore no opportunity for preventing onset of hypoglycemia

[0004] The above problem is solved by a system wherein the EEG monitor is configured to submit a warning signal to the insulin delivery device if an upcoming onset of hypoglycemia is identified by the EEG signal processor. The warning message will cause the insulin delivery device to restrict the insulin delivery for a predetermined time period, and a warning is provided to said person or to a caregiver.

[0005] Restriction of the insulin delivery may imply pausing the insulin delivery completely for a predetermined period or, it may imply limiting the insulin delivery to some extent for a predetermined period. The length of the predetermined period as well as the extent to which insulin delivery is limited may depend on the warning message history, e.g. if more warning messages have already been submitted within a relatively short time. Also, the risk of hyperglycemia if the restriction period is

too long may be considered.

[0006] An advantage of the solution is that an automatic restriction of insulin delivery is provided, thereby improving the safety of the system.

5 **[0007]** An advantage of the system is that it will allow for a more precise adjustment of the insulin delivery aiming at holding the blood glucose level within an optimum interval. This better adjustment may be achieved by the use of insulin which is more rapidacting. This can be applied safely due to the extra safety provided by the EEG monitoring. The person applying the system will have the benefit of an improved long term health.

10 **[0008]** In an embodiment the system also comprises a glucose monitor. This may e.g. be an automatic blood glucose level detector or a continuous glucose monitor (CGM) automatically monitoring the tissue fluid glucose. This makes it possible to evaluate results found from the EEG signal with reference to actual glucose levels. Such a glucose monitor may regularly be calibrated to standard blood glucose measurements.

15 **[0009]** In an embodiment the insulin delivery device is configured to notify said EEG monitor about a service needed on the insulin delivery device. Such a service could e.g. be the need to recharge or replace battery, to refill the insulin reservoir, or to have some malfunction repaired. The EEG monitor may then notify the user of the system.

20 **[0010]** In an embodiment the system further comprises a glucagon or glucose delivery device controllable by said EEG monitor. This facilitates that the system may be able to prevent or to remedy a state of hypoglycemia.

25 **[0011]** In an embodiment the insulin delivery device is configured to deliver insulin only after having controlled that the EEG monitor is functioning and is capturing the EEG signal of the person wearing the system. This prevents that a malfunctioning of the EEG monitor can result in continued delivery of insulin to the person even if there is an upcoming onset of hypoglycemia. In this case a notification should also be given to the person that the EEG monitor is out of function. In practice a malfunctioning EEG monitor may result in that the person is being instructed from the insulin pump to perform a more frequent control of the blood glucose level, and that a minor restriction of the insulin delivery is introduced. I.e. the risk of ending up with hyperglycemia in the effort to avoid hypoglycemia should be avoided.

30 **[0012]** In an embodiment the EEG monitor comprises an antenna for the wireless communication link, said antenna being adapted for being placed outside the skin layer of the person and outside the ear canal. This position of the antenna facilitates optimum conditions for a reliable electromagnetic communication with the insulin delivery device and other units of the system.

35 **[0013]** In an embodiment an automatic blood glucose level detector or a CGM is connected to the EEG monitor or to the insulin pump. This facilitates continuous data on the glucose level, which can improve the ability of the system to detect an upcoming onset of hypoglycemia.

In an embodiment the EEG monitor is adapted to send a request to measure the blood glucose level in the event that an upcoming onset of hypoglycemia is identified.

In an embodiment the EEG sensing part is arranged subcutaneously at the scalp. This gives the EEG electrodes a good and reliable contact to the tissue and will give a clear EEG signal.

[0014] In an embodiment the EEG monitor comprises a speaker adapted for providing sound messages and alarms from both said EEG monitor and said insulin delivery device to said person. The arrangement of the EEG monitor at the ear region makes a speaker in the EEG monitor easy to hear, without people surrounding the person wearing the system hearing any messages or alarms.

[0015] In a second aspect the invention is directed at a method for adjusting an insulin delivery device to be worn by a person, where the method comprises the steps of

- providing an insulin delivery device configured to release insulin into the body of the person;
- Providing an EEG monitor configured to be arranged in the ear region of the person, where the EEG monitor has an EEG sensing part comprising EEG electrodes. The EEG sensing part being configured to be arranged subcutaneously at the scalp or in the ear canal, and the EEG monitor comprises an EEG signal processor configured to be arranged at the ear and adapted for identifying onset of hypoglycemia;
- Establishing a wireless communication link between the EEG monitor and the insulin delivery device;
- The EEG signal processor configured to be arranged to analyze an EEG signal to be sampled by the EEG sensing part in order to identify an upcoming onset of hypoglycemia; and
- Configuring the EEG monitor to submit a warning signal to the insulin delivery device in case an upcoming onset of hypoglycemia is identified. The warning message being capable of causing the insulin delivery device to restrict the insulin delivery for a predetermined time period. The EEG monitor further provides a warning to the person or to a caregiver.

[0016] Embodiments of the invention will now be explained in further detail with reference to the figures.

Figure 1 illustrates a system having an EEG monitor with a sensing part and a signal processor, where the monitor is in communication with an insulin pump, which may receive input from a blood glucose monitor or a CGM.

Figure 2 illustrates the system of figure 1 also comprising a Glucagon pump and an external unit.

Figure 3 illustrates the EEG monitor having an EEG sensing part and an EEG signal processor.

Figure 4 illustrates an example of an EEG sensing part.

Figure 5 illustrates an example of an insulin pump.

[0017] Figure 1 shows a system comprising an EEG monitor 1, an insulin delivery device or an insulin pump 2 and a glucose monitor 3 in the form of a blood glucose monitor or a CGM. The EEG monitor 1 and the insulin pump 2 are connected by a wireless connection 6. The glucose monitor 3 may be manual or automatic and has the possibility for entering a measured glucose level into the insulin pump 2.

[0018] The EEG monitor 1 is adapted to be arranged in the ear region of the person who is to be monitored. The EEG monitor 1 comprises two main parts: An EEG sensing part 12 and an EEG signal processor 11. Further to this the EEG monitor also comprises a component, e.g. a speaker 13, for providing alarms or messages. The EEG monitor 1 will also comprise a power supply, e.g. in the form of a battery.

[0019] The EEG sensing part 12 has electrodes for detecting an EEG signal. The EEG sensing part 12 comprises EEG electrodes which may be arranged subcutaneously at the scalp, preferably in a region extending from behind the ear. The EEG electrodes may also be arranged as surface skin electrodes in the ear canal. The EEG electrodes may be of the type having direct electric connection to the tissue or the skin, or they may be of the capacitive type, where a dielectric material is arranged between the electric conductive part of the electrode and the tissue or skin. The advantages of having the EEG electrodes either subcutaneously or in the ear canal are that good and clear EEG signals can be received, and that the electrodes in these positions will be more protected from picking up electromagnetic noise from the surroundings compared to a position external on the scalp.

[0020] The subcutaneous or ear canal positions of the EEG electrodes are preferred also from a cosmetic perspective. The subcutaneous or ear canal positions are furthermore preferred from a reliability point of view since these positions facilitate durable and stable contact to either tissue or skin, i.e. the risk of losing contact, and thereby not being able to detect an EEG signal, is significantly smaller compared to an external electrode which is more likely to lose contact, e.g. during exercise or other daily activities.

[0021] The EEG signal processor 11 is adapted to receive the EEG signal from the EEG sensor and to process the signal in order to extract specific features from the measured EEG signal. This feature extraction can be related to e.g. specific frequencies and amplitudes in the EEG signal. Such extracted features may be classified in order to determine if they are relevant to identifying an

upcoming onset of hypoglycemia. The EEG signal processor is preferably connected to a speaker in order to provide an alarm of an upcoming onset of hypoglycemia to the user of the system.

[0022] A warning signal concerning an identified upcoming onset of hypoglycemia will also be submitted to the insulin pump 2 to which the EEG monitor has a wireless connection 6.

[0023] This wireless connection 6 may have any form, but an electromagnetic based or radio connection would often be a preferred choice. The protocol for the connection could be based on Bluetooth, where a low power Bluetooth connection would be preferred.

[0024] The insulin pump 2 administers insulin by subcutaneous infusion to the user of the system. The insulin pump typically delivers a continuous basal dose, possibly supplemented with a bolus dose in connection with meals or high blood glucose level. Both basal rate and bolus insulin delivery will be adapted to the needs of the individual user. The input from glucose monitoring is applied in the ongoing adjustment of the insulin dose administered.

[0025] Different types of glucose monitors 3 may be applied. One type, the finger stick measurement, is based on obtaining a drop of blood from a small prick in a finger, and placing this on a small strip which is analyzed in a blood glucose meter. The result may be transferred to the insulin pump, either directly e.g. wirelessly, or by the user entering the result to the insulin pump.

[0026] An alternative to the direct blood glucose monitoring is, as mentioned, a CGM which measures the glucose level in the tissue fluid. This may include a sensor placed subcutaneously, e.g. by a needle penetrating the skin, where the needle and the spot of penetration are changed with defined intervals. Also, a glucose sensor may be more permanently implanted subcutaneously. Such an implanted glucose sensor is in connection, preferably wirelessly, with an external part which can be a separate part or it can be part of the insulin pump.

[0027] When the system of figure 1 is in operation, the insulin pump 2 will usually be administering a basal dose supplemented with bolus doses, where the bolus dose may be administered by request of the user. Glucose level is tested at selected times or continuously, and the doses from the insulin pump may be adjusted accordingly. The EEG monitor 1 will monitor the EEG signal continuously, and in the case an upcoming onset of hypoglycemia is detected, a warning signal is sent to the insulin pump and a direct alarm is provided to the user preferably by use of the speaker. If an automatic glucose monitor is part of the system, an alarm from the EEG monitor of an upcoming onset of hypoglycemia should result in the request of a glucose measurement.

[0028] If the EEG monitor indicates that onset of hypoglycemia may be upcoming, but the automatic glucose monitor indicates normal glucose level, a manual finger stick type blood glucose measurement could be requested as a control.

[0029] The insulin pump is set up to restrict the delivery of insulin to the user when receiving the warning message or signal. Preferably, a physician with insight into the user's diabetes has provided advice, or has decided, on the exact programming of the insulin pump, including programming of the response to any warning signals. Simultaneously with the warning signal to the insulin pump, an alarm is provided to the user. The user should be instructed in advance on how to react to such an alarm, e.g. immediate measurement of the blood glucose level and/or immediate intake of some specific nutrient increasing the blood glucose level.

[0030] The exact restriction of the insulin delivery may also depend on the input from a CGM connected to the insulin pump. Depending on the diabetes history of the user it may be that a restriction in insulin delivery is introduced if either the EEG monitor or the CGM measure values indicating that hypoglycemia may be close to onset. It could also be that the level of restriction is determined based on the features in the EEG signal detected by the EEG monitor and on the exact measurement by the CGM. This means that the EEG monitor should submit information related to the features extracted by the EEG signal processor to the insulin pump together with the warning message.

[0031] Figure 2 shows the system of figure 1 to which a glucagon pump 4 has been added. A glucagon pump facilitates that the system may be able to prevent or to overcome an incidence of hypoglycemia. This can be done by having an automatic activation of the glucagon pump resulting in the administration of a glucagon dose, which will increase the blood glucose level. This automatic activation may be triggered if the EEG monitor detects a state of hypoglycemia. A glucagon pump may also be controlled by the person carrying the system. Thereby, the person could administer a glucagon dose in the situation where the EEG monitor submits an alarm on an upcoming onset of hypoglycemia, maybe after having controlled the actual blood glucose level.

[0032] Further to the glucagon pump, but independently from this, the system may be provided with an external unit 5. This external unit may have several functions, such as user interface, storing of data, internet connection, and tracking and storing relevant habits of the person carrying the system. Relevant habits may be when the person administers boluses, eats, exercises, or measures the blood glucose manually, which measurement may be entered through the external unit and forwarded to the insulin pump. The external unit may be the person's mobile phone, watch or any small portable computer device, provided with software for the purpose. The connection to one or more components of the system should be wireless, e.g. a Bluetooth connection.

[0033] The external unit 5 may thus be applied as interface between the user and the components of the system. The user may enter relevant information such as manually measured blood glucose level, information on meals or anything the user might eat, response to or can-

cellation of alarms, or any user selected adjustments to the settings of the system.

[0034] The external unit 5 may also be applied for presenting information from one or more components of the system to the user. This could be further details in relation to alarms given to the person, e.g. through the speaker. Such details could be instructions on the actions to be taken by the person. Also, information on the operational status of any unit in the system which is connected to the external unit 5 may be provided to the user through the external unit. Examples of this could be battery charging levels or the reservoir levels of the insulin pump or the glucagon pump.

[0035] The external unit 5 may also be applied for storage of data. This could be the EEG signal sampled in connection with an event in the EEG signal triggering an alarm. Sampling and collecting the EEG signals related to the triggering of an alarm may be applied for improving the algorithms applied for the extraction of specific features from the EEG signal, and for the classification of those features. Especially, samples of EEG signals in connection with alarms could be applied for adjusting the level or threshold value where an alarm should be provided. For this purpose a measured blood glucose at the time of the alarm will be relevant, and could be sent from an automatic blood glucose monitor or CGM to the external unit 5, or it could be sent from the unit into which the result of a finger stick measurement were entered to the external unit.

[0036] The external unit 5 may also have connection to the internet, which may be applied for uploading EEG signal samples directly to a physician, who might also be able to adjust the settings of the system over this internet connection. Alarms may also be forwarded, e.g. to close relatives or helpers, over the internet, or alarms may be transmitted directly to one or more preselected telephone numbers, web-pages or IP-addresses.

[0037] Figure 3 shows an example of the EEG monitor in the system in more details. The EEG monitor 1 comprises an external EEG signal processor 11 and an implantable EEG sensing part 12. The EEG sensing part 12, suitable for being subcutaneously positioned behind the ear of a person, comprises subcutaneous EEG electrodes 17 connected to an electronic module 60. The number of EEG electrodes is at least two. Often at least three electrodes or more are preferred. The electronic module 18, which is shown in more detail in figure 4, often comprises an A/D converter 24 and a communication controller 26, and a voltage regulator 27. The electrodes 17 are connected to the A/D converter; the communications controller is connected to a first coil 20 of an inductive link 19.

[0038] The EEG signal processor 11 comprises a signal processor 10 having a controller (not shown) connected to a second coil 21 of the inductive link 19. The signal processor 10 is further connected to a battery (not shown) for power supply and to a loudspeaker 13 for providing an acoustic signal, e.g. an alarm in the event

that an upcoming onset of hypoglycemia is identified. The EEG signal processor part 11 also comprises a memory 16, e.g. for logging of data, as well as a radio 15 with an antenna 14, for wireless communication with other units in the system, and e.g. with the external unit.

[0039] When in use, the EEG signal processor 11 may be placed behind the ear of a person for whom monitoring of an EEG signal is desired, and in the vicinity of a subcutaneously implantable EEG sensing part 12, which preferably is implanted right below the skin and slightly behind the ear of the user and positioned in such a way that a reliable, electrical EEG signal may be detected by the electrodes 17.

[0040] As illustrated in more details in figure 4 the electrodes 17 of the EEG sensing part 12 can be arranged in one wire 23 having the electrodes 17 arranged with contact to the tissue in limited areas along the wire 23.

[0041] The electrodes 17 pick up EEG signals as a varying electrical voltage potential and feed the varying electrical voltage to the A/D converter 24 in the electronic module 18. The A/D converter 24 converts the varying electrical voltage into a digital signal and presents this digital signal to a data packet controller 25 which is part of the electronic module 18. The data packet controller 25 arranges the digital signal into a stream of data packets according to a predetermined communications protocol, and feeds the resulting stream of data packets to the communications controller 26.

[0042] The communications controller 26 is configured to energize the electronic module 18 electromagnetically by receiving energy from the second coil 21 of the external EEG signal processor 11 by the first coil 20. The electromagnetic energy received in the first coil 20 is transferred to the voltage regulator 27 which, together with a ceramic capacitor 28, is applied as a power source for the electronic module 18.

[0043] Furthermore, the communications controller 26 takes data packets representing the EEG signals from the electrodes 17 and transfers this digitized EEG signal from the EEG sensing part through the inductive link by modulating the load on the power received in the first coil 20 from the second coil 21. This modulated load is detectable from the EEG signal processor 11, where the modulation of the load is converted into an electrical signal suitable for being continuously decoded and analyzed by the signal processor 10.

[0044] The analysis of the EEG signal in order to identify an upcoming onset of hypoglycemia may be based on different algorithms. One example on how this analysis can be performed is given in WO 2012/069549 A1.

[0045] Depending on the results of the analysis of the EEG signals, decisions may be taken by the signal processor 10 to activate the loudspeaker 13 sounding an alarm if upcoming onset of hypoglycemia is identified.

[0046] The EEG electrodes 17 in the embodiment shown in figure 3 are arranged to be implanted subcutaneously behind the ear of a user in order to provide a signal suitable for detection by the electronic module of

the EEG sensing part 12. A typical output signal from the EEG electrode has a magnitude in the range of approximately 1 μ V to 100 μ V. Muscular contractions usually generate voltage levels of a magnitude of 10 mV, but such signals are filtered out by the system. The intrinsic noise level of the electrode is about 1 μ V RMS measured over a bandwidth from 0.1 to 100 Hz, and the useable bandwidth of the output signal is 0.1 to 40 Hz.

[0047] The EEG sensing part 12 is encased in a bio-compatible material (not shown), such as a ceramic. The electrodes are also made from a bio-compatible metal, such as a platinumiridium alloy. When the EEG signal processor 11 is worn behind the ear (as a behind-the-ear hearing aid) where the implant has been positioned, the second coil 21 of the EEG signal processor 11 will be a few millimeters from the first coil 20 of the EEG sensing part 12. This facilitates communication and transfer of power between the EEG signal processor 11 and the EEG sensing part 12. The two coils should preferably be closely aligned, whereby a more efficient transfer of power and a more reliable communication can be achieved.

[0048] The EEG sensing part of the EEG monitor is described as implantable in relation to figure 3 and 4. However, the EEG sensing part can also be arranged in the ear canal with the electrodes detecting the EEG signal from the skin surface of the ear canal. An example of an ear plug with electrodes for this purpose is given in WO 2011/000383 A1 (see e.g. figure 2 of this publication)

[0049] Figure 5 shows an example of an insulin pump 2 for the system. The insulin pump has display 31 for communication with the user, and a controller 32 for controlling the delivery of insulin to the person wearing the insulin pump. The insulin pump also comprises a radio 33 with an antenna 34 for the communication with other units of the system. Further the insulin pump comprises a reservoir 36 for insulin and a motor 37 for moving a piston in order to deliver insulin through an infusion set comprising a cannula 35.

[0050] The wireless connection between the EEG monitor and the insulin pump should have a protocol ensuring a high degree of reliability in the communication. The protocol should confirm that there is a connection at regular time intervals, e.g. once a second, and if connection has been lost for more than e.g. 15 seconds a notification may be provided to the person wearing the system or to a caregiver. In the situation where the wireless connection is lost, both the insulin pump and the EEG monitor should continue functioning according to their programmed settings. In that case the person using the system should be clearly notified, and a caregiver might be notified as well. In case the EEG monitor detects an upcoming onset of hypoglycemia in this situation where the wireless connection is lost, the warning provided to the person and/or caregiver should clearly emphasize that no automatic restriction (e.g. pause or limitation) of the insulin delivered from the insulin pump can be performed.

[0051] If the connection between insulin pump and EEG monitor is lost, any action the insulin pump is programmed to take should depend on the availability of automatic and continuous blood glucose measurements or a CGM. One option is that bolus doses are only delivered after notification and confirmation by the user. Also, if the system comprises a glucagon pump to which the EEG monitor continues to have a fully functional connection, such a glucagon pump would offer safety, if the EEG monitor is able to control the delivery of glucagon in case an upcoming onset of hypoglycemia is identified. Any such programming should be based on the individual user's needs, and should therefore be based on consultation with a physician knowing the diabetic status of the person.

[0052] Speech messages or notifications from any device in the system may be provided to the person using the system through the EEG monitor. This could include information from the insulin pump that the insulin reservoir has reached a level where a refill is advisable, or that the batteries in the insulin pump needs recharging or replacement. For safety reasons it is preferred that the insulin pump has a separate alarm means in order to provide alarms also if the wireless connection between the EEG monitor and the insulin pump should be lost.

Claims

1. A system for adjusting the blood glucose level of a person, comprising

- an insulin delivery device configured to release insulin into the body of said person,
- an EEG monitor (1) having an EEG sensing part (12) comprising EEG electrodes (17), said EEG monitor (1) being adapted for being arranged in the ear region of the person with said EEG sensing part (12) arranged subcutaneously at the scalp or arranged in the ear canal, said EEG monitor (1) comprising an EEG signal processor (11) arranged at the ear and adapted for identifying onset of hypoglycemia, and
- a wireless communication link between said EEG monitor (1) and said insulin delivery device,

wherein said EEG monitor (1) is configured to submit a warning signal to said insulin delivery device if an upcoming onset of hypoglycemia is identified by said EEG signal processor (11), said warning message causing said insulin delivery device to restrict the insulin delivery for a predetermined time period, and wherein a warning is provided to said person or to a caregiver.

2. The system according to claim 1, further comprising a glucose monitor (3).

3. The system according to claim 1, wherein said insulin delivery device is configured to notify said EEG monitor (1) about a service needed on the insulin delivery device.
4. The system according to claim 1 or 2, wherein said system further comprises a glucagon or glucose delivery device controllable by said EEG monitor (1).
5. The system according to any one of the preceding claims, wherein said insulin delivery device is configured to deliver insulin only after having controlled that said EEG monitor (1) is functioning and is capturing the EEG signal of said person.
6. The system according to any one of the preceding claims, wherein said EEG monitor (1) comprises an antenna (14) for said wireless communication link, said antenna (14) being adapted for being placed outside the skin layer and outside the ear canal.
7. The system according to claim 2, wherein said glucose monitor (3) is automatic, and is connected to said EEG monitor (1) or to said insulin pump.
8. The system according to claim 7, wherein said EEG monitor (1) is adapted to send a request to measure the glucose level in the event that an upcoming onset of hypoglycemia is identified.
9. The system according to any one of the preceding claims, wherein said EEG sensing part (12) is arranged subcutaneously at the scalp.
10. The system according to any one of the preceding claims, wherein said EEG monitor (1) comprises a speaker (13) adapted for providing sound messages and alarms from both said EEG monitor (1) and from said insulin delivery device to said person.
11. A method for adjusting an insulin delivery device to be worn by a person, said method comprising the steps of
 - providing an insulin delivery device configured to release insulin into the body of said person,
 - providing an EEG monitor (1) configured to be arranged in the ear region of said person, said EEG monitor (1) having an EEG sensing part (12) comprising EEG electrodes (17), said EEG sensing part (12) being configured to be arranged subcutaneously at the scalp or in the ear canal, said EEG monitor (1) comprising an EEG signal processor (11) configured to be arranged at the ear and adapted for identifying onset of hypoglycemia,
 - establishing a wireless communication link between said EEG monitor (1) and said insulin de-

livery device,

- said EEG signal processor (11) configured to be arranged to analyze an EEG signal to be sampled by said EEG sensing part (12) in order to identify an upcoming onset of hypoglycemia,
- configuring said EEG monitor (1) to submit a warning signal to said insulin delivery device in case an upcoming onset of hypoglycemia is identified, said warning message being capable of causing said insulin delivery device to restrict the insulin delivery for a predetermined time period, and
- provide a warning to said person or to a caregiver in the case that an upcoming onset of hypoglycemia is identified.

Patentansprüche

1. System zur Einstellung des Blutzuckerspiegels einer Person, umfassend
 - eine Vorrichtung zur Insulinabgabe, die konfiguriert ist, um Insulin in den Körper der Person freizugeben,
 - einen EEG-Monitor (1), der ein EEG-Elektroden (17) umfassendes EEG-Fühlteil (12) aufweist, wobei der EEG-Monitor (1) angepasst ist, um in der Ohrregion der Person angeordnet zu werden, wobei das EEG-Fühlteil (12) subkutan unter der Kopfhaut angeordnet ist oder im Gehörgang angeordnet ist, wobei der EEG-Monitor (1) einen EEG-Signalprozessor (11) umfasst, der am Ohr angeordnet ist und angepasst ist, um den Beginn von Hypoglykämie zu identifizieren, und
 - eine drahtlose Kommunikationsverbindung zwischen dem EEG-Monitor (1) und der Vorrichtung zur Insulinabgabe,
 wobei der EEG-Monitor (1) konfiguriert ist, um ein Warnsignal an die Vorrichtung zur Insulinabgabe abzugeben, wenn von dem EEG-Signalprozessor (11) ein bevorstehender Beginn von Hypoglykämie identifiziert wird, wobei die Warnmeldung verursacht, dass die Vorrichtung zur Insulinabgabe die Insulinabgabe für eine vorbestimmte Zeitspanne einschränkt, und wobei eine Warnung für die Person oder einen Pfleger bereitgestellt wird.
2. System nach Anspruch 1, weiter umfassend einen Glukosemonitor (3).
3. System nach Anspruch 1, wobei die Vorrichtung zur Insulinabgabe konfiguriert ist, um dem EEG-Monitor (1) einen erforderlichen Service an der Vorrichtung zur Insulinabgabe zu melden.

4. System nach Anspruch 1 oder 2, wobei das System weiter eine von dem EEG-Monitor (1) steuerbare Vorrichtung zur Glucagon- oder Glukoseabgabe umfasst.
5
5. System nach einem der vorstehenden Ansprüche, wobei die Vorrichtung zur Insulinabgabe konfiguriert ist, um Insulin nur abzugeben, nachdem kontrolliert wurde, dass der EEG-Monitor (1) funktioniert und das EEG-Signal von der Person erfasst.
10
6. System nach einem der vorstehenden Ansprüche, wobei der EEG-Monitor (1) eine Antenne (14) für die drahtlose Kommunikationsverbindung umfasst, wobei die Antenne (14) angepasst ist, um außerhalb der Hautschicht und außerhalb des Gehörgangs platziert zu werden.
15
7. System nach Anspruch 2, wobei der Glukosemonitor (3) automatisch ist und an dem EEG-Monitor (1) oder der Insulinpumpe angeschlossen ist.
20
8. System nach Anspruch 7, wobei der EEG-Monitor (1) angepasst ist, um eine Aufforderung zur Messung des Glukosespiegels zu senden, wenn ein bevorstehender Beginn von Hypoglykämie identifiziert wird.
25
9. System nach einem der vorstehenden Ansprüche, wobei das EEG-Fühlteil (12) subkutan unter der Kopfhaut angeordnet ist.
30
10. System nach einem der vorstehenden Ansprüche, wobei der EEG-Monitor (1) einen Lautsprecher (13) umfasst, der angepasst ist, um Tonmeldungen und -alarme sowohl vom EEG-Monitor (1) als auch von der Vorrichtung zur Insulinabgabe für die Person bereitzustellen.
35
11. Verfahren zur Einstellung einer Vorrichtung zur Insulinabgabe, die von einer Person zu tragen ist, wobei das Verfahren umfasst die Schritte
40
 - Bereitstellen einer Vorrichtung zur Insulinabgabe, die konfiguriert ist, um Insulin in den Körper der Person freizugeben,
45
 - Bereitstellen eines EEG-Monitors (1), der konfiguriert ist, um in der Ohrregion der Person angeordnet zu werden, wobei der EEG-Monitor (1) ein EEG-Elektroden (17) umfassendes EEG-Fühlteil (12) aufweist, wobei das EEG-Fühlteil (12) konfiguriert ist, um subkutan unter der Kopfhaut oder im Gehörgang angeordnet zu werden, wobei der EEG-Monitor (1) einen EEG Signalprozessor (11) umfasst, der konfiguriert ist, um am Ohr angeordnet zu werden, und angepasst ist, um den Beginn von Hypoglykämie zu identifizieren,
50

- Aufbauen einer drahtlosen Kommunikationsverbindung zwischen dem EEG-Monitor (1) und der Vorrichtung zur Insulinabgabe,
- wobei der EEG-Signalprozessor (11) konfiguriert ist, um angeordnet zu werden, um ein EEG-Signal zu analysieren, das vom EEG-Fühlteil (12) abgetastet wurde, um einen bevorstehenden Beginn von Hypoglykämie zu identifizieren,
- Konfigurieren des EEG-Monitors (1), um ein Warnsignal an die Vorrichtung zur Insulinabgabe abzugeben, wenn ein bevorstehender Beginn von Hypoglykämie identifiziert wird, wobei die Warnmeldung in der Lage ist zu verursachen, dass die Vorrichtung zur Insulinabgabe die Insulinabgabe für eine vorbestimmte Zeitspanne einschränkt, und
- Bereitstellen einer Warnung an die Person oder an einen Pfleger, wenn ein bevorstehender Beginn von Hypoglykämie identifiziert wird.

Revendications

1. Système d'ajustement du taux de glycémie d'une personne comprenant
 - un dispositif d'administration d'insuline configuré pour libérer de l'insuline dans le corps de ladite personne,
 - un moniteur EEG(1) ayant une partie de détection EEG(12) comprenant des électrodes EEG (17), ledit moniteur EEG (1) étant à même d'être agencé dans la région auditive de la personne avec ladite partie de détection EEG (12) agencée par voie sous-cutanée sur la cuir chevelu ou agencée dans le canal auditif, ledit moniteur EEG (1) comprenant un processeur de signal EEG (11) agencé dans l'oreille et adapté pour identifier l'apparition d'une hypoglycémie et
 - une liaison de communication sans fil entre ledit moniteur EEG (1) et ledit dispositif d'administration d'insuline,
 dans lequel ledit moniteur EEG (1) est configuré pour soumettre un signal d'avertissement audit dispositif d'administration d'insuline si une apparition prochaine d'hypoglycémie est identifiée par ledit processeur de signal EEG (11), ledit message d'avertissement amenant ledit dispositif d'administration d'insuline à limiter l'administration d'insuline pendant une période de temps prédéterminée, et dans lequel un avertissement est fourni à ladite personne ou à un soignant.
2. Système selon la revendication 1, comprenant en outre un moniteur de glucose (3).

3. Système selon la revendication 1, dans lequel ledit dispositif d'administration d'insuline est configuré pour notifier audit moniteur EEG (1) sur un entretien nécessité par le dispositif d'administration d'insuline. 5
4. Système selon la revendication 1 ou 2, dans lequel ledit système comprend en outre un dispositif d'administration de glucagon ou de glucose qui peut être commandé par ledit moniteur EEG (1). 10
5. Système selon l'une quelconque des revendications précédentes, dans lequel ledit dispositif d'administration d'insuline est configuré pour administrer de l'insuline uniquement après avoir commandé que ledit moniteur EEG (1) fonctionne et capture le signal EEG de ladite personne. 15
6. Système selon l'une quelconque des revendications précédentes, dans lequel ledit moniteur EEG (1) comprend une antenne (14) pour ladite liaison de communication sans fil, ladite antenne (14) étant à même d'être placée à l'extérieur de la couche de peau et à l'extérieur du canal auditif. 20
7. Système selon la revendication 2, dans lequel ledit moniteur de glucose (3) est automatique et est raccordé audit moniteur EEG (1) ou à ladite pompe à insuline. 25
8. Système selon la revendication 7, dans lequel ledit moniteur EEG (1) est à même d'envoyer une demande du taux de glycémie dans le cas où une apparition prochaine d'hypoglycémie est identifiée. 30
9. Système selon l'une quelconque des revendications précédentes, dans lequel ladite partie de détection EEG (12) est agencée par voie sous-cutanée sur le cuir chevelu. 35
10. Système selon l'une quelconque des revendications précédentes, dans lequel ledit moniteur EEG (1) comprend un haut-parleur (13) qui est à même de fournir des messages et des alarmes sonores à partir à la fois dudit moniteur EEG (1) et dudit dispositif d'administration d'insuline à ladite personne. 40
45
11. Procédé d'ajustement d'un dispositif d'administration d'insuline à porter par une personne, ledit procédé comprenant les étapes consistant à 50
 - fournir un dispositif d'administration d'insuline configuré pour libérer de l'insuline dans le corps de ladite personne,
 - fournir un moniteur EEG (1) configuré pour être agencé dans la région auditive de ladite personne, ledit moniteur EEG (1) ayant une partie de détection EEG (12) comprenant des électrodes EEG (17), ladite partie de détection EEG (12) 55

étant configurée pour être agencée par voie sous-cutanée sur le cuir chevelu ou dans le canal auditif, ledit moniteur EEG (1) comprenant un processeur de signal EEG (11) configuré pour être agencé dans l'oreille et adapté pour identifier l'apparition d'une hypoglycémie,

- établir une liaison de communication sans fil entre ledit moniteur EEG (1) et ledit dispositif d'administration d'insuline,
- ledit processeur de signal EEG (11) configuré pour être agencé afin d'analyser un signal EG à échantillonner par ladite partie de détection EEG (12) afin d'identifier une apparition prochaine d'hypoglycémie,
- configurer ledit moniteur EEG (1) pour soumettre un signal d'avertissement audit dispositif d'administration d'insuline dans le cas de l'identification d'une apparition prochaine d'hypoglycémie, ledit message d'avertissement étant à même d'amener ledit dispositif d'administration d'insuline à limiter l'administration d'insuline pendant une période de temps prédéterminée et
- fournir un avertissement à ladite personne ou à un soignant dans le cas où une apparition prochaine d'hypoglycémie est identifiée.




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 8348842 B1 [0002]
- US 6572542 B1 [0002]
- WO 2012069549 A1 [0044]
- WO 2011000383 A1 [0048]

专利名称(译)	用于调节人的血糖水平的系统和用于调节胰岛素输送装置的方法		
公开(公告)号	EP3247271B1	公开(公告)日	2018-12-05
申请号	EP2015700491	申请日	2015-01-19
[标]申请(专利权)人(译)	T&W工程公司		
申请(专利权)人(译)	同维工程A / S		
当前申请(专利权)人(译)	同维工程A / S		
[标]发明人	TPHOLM RICHARD JENSEN RASMUS STIG CHRISTENSEN ERIK SKOV MADSEN RASMUS ELSBORG		
发明人	TØPHOLM, RICHARD JENSEN, RASMUS STIG CHRISTENSEN, ERIK SKOV MADSEN, RASMUS ELSBORG		
IPC分类号	A61B5/00 A61B5/0476 A61B5/0478 A61B5/157 A61B5/15 A61B5/155 A61B5/145 A61M5/142 A61M5/172		
CPC分类号	A61B5/4839 A61B5/0476 A61B5/0478 A61B5/14532 A61B5/150022 A61B5/15087 A61B5/150877 A61B5/155 A61B5/157 A61B5/6814 A61B5/6817 A61B5/7405 A61B5/746 A61M5/142 A61M5/14244 A61M5/14276 A61M5/1723 A61M2202/0486 A61M2205/18 A61M2205/3569 A61M2205/581 A61M2230/10 A61M2230/201		
其他公开文献	EP3247271A1		
外部链接	Espacenet		

摘要(译)

一种用于调节血糖水平的系统，包括配置成将胰岛素释放到人体内的胰岛素输送装置，以及具有包括EEG电极的EEG感测部分的EEG监测器。EEG监测器可以布置在人的耳部区域中，其中EEG感测部分皮下地布置在头皮处或布置在耳道中。EEG监测器包括EEG信号处理器，其布置在耳朵处并且适于识别低血糖的发作。该系统还包括EEG监测器和胰岛素输送装置之间的无线链路。EEG监测器被配置为如果识别出即将发生的低血糖，则向胰岛素输送装置提交警告信号。警告消息将使胰岛素输送装置限制胰岛素输送达预定时间，并且向人或护理人员提供警告。




Fig. 1




Fig. 2